Extraocular muscle volume reduction in a patient treated with two courses of teprotumumab for thyroid eye disease.

Hanna Richkind, Marissa K Shoji, Megan Routzong, David Granet, Don O Kikkawa, Jolene C Rudell

Abstract readCase Reports

In one paragraph

Article in American journal of ophthalmology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hanna RichkindRatner Children's Eye Center of the Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.

Marissa K ShojiDivision of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.

Megan RoutzongDepartment of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Diego, Sanford Consortium for Regenerative Medicine, La Jolla, CA, 92037, USA.

David GranetRatner Children's Eye Center of the Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.

Don O KikkawaDivision of Oculofacial Plastic and Reconstructive Surgery, Viterbi Family Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.

Jolene C RudellRatner Children's Eye Center of the Shiley Eye Institute, University of California San Diego, La Jolla, CA, USA.

Funding

Role of a craniosynostosis associated fibroblast growth factor receptor mutation in extraocular musclesK08EY034930 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jolene Rudell · 2023 to 2026

$1.1M

NEI NIH HHS K08 EY034930

6 · The paper itself

Abstract

Purpose: To report magnetic resonance imaging (MRI) extraocular muscle (EOM) volume analysis in a patient with thyroid eye disease (TED) who was treated with two full courses of teprotumumab. Observations: An 84-year-old man with TED received two full courses (16/16 infusions) of teprotumumab. At the initial presentation, he had decreased visual acuity, proptosis, and diplopia. Imaging at this time illustrated enlarged EOMs, predominantly on the left side. After his first course of teprotumumab, his symptoms improved. However, he experienced disease reactivation 7 months later. A follow-up MRI revealed reduced EOM volume compared to baseline, though the patient reported recurrent symptoms. A second course of teprotumumab (8/8 infusions) was initiated, leading to clinical improvement. Six months after completion of his second teprotumumab course, a third MRI showed further reduction in EOM volumes compared to both baseline and pre-retreatment imaging. Conclusion: This case demonstrates the potential for continued radiographic and clinical improvement in TED patients after retreatment with teprotumumab. Further studies may clarify the role of EOM volume as a marker for treatment efficacy.

Indexed as

Extraocular muscle volumeGraves' diseaseRetreatmentTeprotumumabThyroid eye disease

Identifiers

PMID41487291

DOI10.1016/j.ajoc.2025.102490

PMCPMC12756564

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.